Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to control advanced lung cancer

NCT ID NCT07407933

Disease control Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 2 times

Summary

This study tests a new drug called YL201 combined with atezolizumab in people with advanced small cell lung cancer. The goal is to find safe doses and see if the combination helps control the disease. About 118 adults who have not had prior treatment for this cancer will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 118 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Feb 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1.18 years of age or older. 2. Histologically or cytologically confirmed diagnosis of ES-SCLC 3. Eastern Cooperative Oncology Group performance status of 0 or 1 4. Adequate hematologic and end-organ function Exclusion Criteria: 1. No prior systemic anti-cancer treatment for ES-SCLC 2. No prior treatment targeting B7H3 or topoisomerase I inhibitor 3. No clinically active brain metastases or spinal cord compression 4. No current or history of interstitial lung disease (ILD)/ pneumonitis 5. No clinically significant cardiovascular disease (eg, New York Heart Association class II to IV congestive heart failure) Other protocol-defined inclusion/ exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Thoracic neoplasms, lung diseases, small cell lung carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung disorder small cell lung carcinoma Thoracic Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Thoracic neoplasms, lung diseases, small cell lung carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    38 sites in 9 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Site 1001

    RECRUITING

    Washington D.C., District of Columbia, 20057, United States

  • Site 1002

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • Site 1004

    RECRUITING

    Louisville, Kentucky, 40202, United States

  • Site 1005

    RECRUITING

    Houston, Texas, 77030, United States

  • Site 1009

    RECRUITING

    Plantation, Florida, 33322, United States

  • Site 1201

    RECRUITING

    Namur, 5000, Belgium

  • Site 1203

    RECRUITING

    Edegem, 2650, Belgium

  • Site 1402

    RECRUITING

    Nice, 06189, France

  • Site 1403

    RECRUITING

    Suresnes, 92150, France

  • Site 1404

    RECRUITING

    Paris, 92210, France

  • Site 1601

    RECRUITING

    Kalocsa, 6300, Hungary

  • Site 1702

    RECRUITING

    Ravenna, 48121, Italy

  • Site 1703

    RECRUITING

    Meldola, 47014, Italy

  • Site 1705

    RECRUITING

    Candiolo, 10060, Italy

  • Site 1801

    RECRUITING

    Przemyśl, 37-700, Poland

  • Site 1802

    RECRUITING

    Otwock, 05-400, Poland

  • Site 1804

    RECRUITING

    Poznan, 60-569, Poland

  • Site 1901

    RECRUITING

    Craiova, 109, Romania

  • Site 1903

    RECRUITING

    Cluj-Napoca, 400015, Romania

  • Site 1904

    RECRUITING

    Bucharest, 022328, Romania

  • Site 2001

    RECRUITING

    Barcelona, 08035, Spain

  • Site 2002

    RECRUITING

    Madrid, 28034, Spain

  • Site 2003

    RECRUITING

    Barcelona, 08023, Spain

  • Site 2004

    RECRUITING

    Madrid, 28223, Spain

  • Site 2005

    RECRUITING

    Madrid, 28040, Spain

  • Site 2006

    RECRUITING

    Barcelona, 08028, Spain

  • Site 2007

    RECRUITING

    Girona, 17007, Spain

  • Site 2008

    RECRUITING

    Seville, Spain

  • Site 2009

    RECRUITING

    Valencia, 46010, Spain

  • Site 2010

    RECRUITING

    Manresa, 08242, Spain

  • Site 2011

    RECRUITING

    Madrid, 28850, Spain

  • Site 2012

    RECRUITING

    Badalona, 08916, Spain

  • Site 2013

    RECRUITING

    Badajoz, 06080, Spain

  • Site 2014

    RECRUITING

    Barcelona, 08017, Spain

  • Site 2015

    RECRUITING

    Valencia, 46026, Spain

  • Site 2019

    RECRUITING

    Madrid, 28050, Spain

  • Site 2201

    RECRUITING

    London, W12 0HS, United Kingdom

  • Site 2203

    RECRUITING

    Edinburgh, EH4 2XU, United Kingdom